Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $4.82 in the prior trading day, Y-Mabs Therapeutics Inc (NASDAQ: YMAB) closed at $4.26, down -11.62%. In other words, the price has decreased by -$11.62 from its previous closing price. On the day, 0.56 million shares were traded. YMAB stock price reached its highest trading level at $4.615 during the session, while it also had its lowest trading level at $3.84.
Ratios:
Our goal is to gain a better understanding of YMAB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.85 and its Current Ratio is at 4.16. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 18, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $23.
On August 16, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.Cantor Fitzgerald initiated its Overweight rating on August 16, 2024, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 07 ’25 when Rossi Michael J sold 3,917 shares for $5.20 per share. The transaction valued at 20,368 led to the insider holds 137,083 shares of the business.
Gad Thomas sold 10,810 shares of YMAB for $56,536 on Mar 07 ’25. The CHIEF BUSINESS OFFICER now owns 202,721 shares after completing the transaction at $5.23 per share. On Mar 07 ’25, another insider, Rajah Vignesh, who serves as the Officer of the company, bought 4,946 shares for $5.20 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, YMAB now has a Market Capitalization of 212073456 and an Enterprise Value of 126215432. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.20 while its Price-to-Book (P/B) ratio in mrq is 2.08. Its current Enterprise Value per Revenue stands at 1.439 whereas that against EBITDA is -5.136.
Stock Price History:
The Beta on a monthly basis for YMAB is 0.42, which has changed by -0.72138655 over the last 52 weeks, in comparison to a change of 0.042615533 over the same period for the S&P500. Over the past 52 weeks, YMAB has reached a high of $17.78, while it has fallen to a 52-week low of $3.86. The 50-Day Moving Average of the stock is -16.25%, while the 200-Day Moving Average is calculated to be -56.83%.
Shares Statistics:
The stock has traded on average 406.29K shares per day over the past 3-months and 241660 shares per day over the last 10 days, according to various share statistics. A total of 44.99M shares are outstanding, with a floating share count of 34.45M. Insiders hold about 23.82% of the company’s shares, while institutions hold 60.15% stake in the company. Shares short for YMAB as of 1743379200 were 3658938 with a Short Ratio of 9.01, compared to 1740700800 on 4725453. Therefore, it implies a Short% of Shares Outstanding of 3658938 and a Short% of Float of 9.689999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 7.0 analysts are actively evaluating the performance of Y-Mabs Therapeutics Inc (YMAB) in the stock market.The consensus estimate for the next quarter is -$0.23, with high estimates of -$0.16 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.63 and -$1.16 for the fiscal current year, implying an average EPS of -$0.94. EPS for the following year is -$0.97, with 7.0 analysts recommending between -$0.75 and -$1.17.
Revenue Estimates
6 analysts predict $19.61M in revenue for the current quarter. It ranges from a high estimate of $20.98M to a low estimate of $18.88M. As of the current estimate, Y-Mabs Therapeutics Inc’s year-ago sales were $19.93MFor the next quarter, 6 analysts are estimating revenue of $20.43M. There is a high estimate of $21.68M for the next quarter, whereas the lowest estimate is $18.9M.
A total of 10 analysts have provided revenue estimates for YMAB’s current fiscal year. The highest revenue estimate was $87.21M, while the lowest revenue estimate was $78.15M, resulting in an average revenue estimate of $82.49M. In the same quarter a year ago, actual revenue was $87.69MBased on 8 analysts’ estimates, the company’s revenue will be $98.02M in the next fiscal year. The high estimate is $129.8M and the low estimate is $86.51M.
